FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED

Their core work

Fujifilm Diosynth Biotechnologies is a large-scale biopharmaceutical contract development and manufacturing organization (CDMO) based in Billingham, UK. Their H2020 involvement centers on advancing bioprocess development — from rapid upstream bioprocessing and CHO (Chinese Hamster Ovary) cell engineering to downstream purification of monoclonal antibodies. They contribute industrial-scale manufacturing expertise to academic-led research consortia, bridging the gap between laboratory biotechnology research and commercial biomanufacturing.

What they specialise in

How they've shifted over time

All three projects were initiated within a narrow window (2015–2016), so there is no meaningful temporal evolution visible in this dataset. Their H2020 participation represents a concentrated burst of engagement in training networks and research actions focused on bioprocessing, rather than a gradual shift in focus. Without projects beyond 2016, it is impossible to determine whether their research interests have evolved since.

Their brief H2020 window focused entirely on biomanufacturing optimization; any future collaboration would likely continue in bioprocess intensification and continuous manufacturing for biologics.

How they like to work

Fujifilm Diosynth has never coordinated an H2020 project, always joining as participant or third party — consistent with an industrial partner providing manufacturing know-how to research-led consortia. With 31 unique partners across 11 countries from just 3 projects, they participated in large, multi-partner training and research networks. This suggests they are comfortable in big consortia but play a supporting industrial role rather than driving the research agenda.

Despite only three projects, they connected with 31 partners across 11 countries, reflecting participation in large Marie Skłodowska-Curie training networks and broad research actions spanning multiple European institutions.

What sets them apart

As a major industrial CDMO, Fujifilm Diosynth brings real-world biomanufacturing scale and operational experience that most academic partners cannot offer. They provide the critical translation layer between laboratory bioprocess research and commercial GMP production. For consortium builders, they are a credible industrial end-user partner that strengthens impact cases for bioprocessing and biologics-related proposals.

Highlights from their portfolio

• AMECRYS
  Largest funded project (EUR 277,360) addressing continuous downstream processing of monoclonal antibodies — a high-value industrial challenge in biologics manufacturing.
• eCHO Systems
  Participated as third party in a project focused on CHO cell engineering, the dominant mammalian expression system used in commercial biopharmaceutical production.